Focus: KalVista is a publicly-traded specialty pharmaceutical company focused on ophthalmology and neurology-based therapies, with 201-500 employees headquartered in Framingham, MA.
Profile data last refreshed 18h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow KalVista Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Help build intelligence for KalVista Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from KalVista Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
16 discontinued, 16 duplicate formulations not shown
Chiesi Group Grows Again in Rare Disease With $1.9B KalVista Acquisition - MedCity News
Chiesi Group Grows Again in Rare Disease With $1.9B KalVista Acquisition MedCity News
Italy's Chiesi buys US-listed KalVista Pharmaceuticals for $1.9 billion - Reuters
Italy's Chiesi buys US-listed KalVista Pharmaceuticals for $1.9 billion Reuters
Chiesi lays out $1.9B to bolster rare disease offerings with KalVista buyout - Fierce Pharma
Chiesi lays out $1.9B to bolster rare disease offerings with KalVista buyout Fierce Pharma
Italian pharma group Chiesi to buy US peer KalVista for $1.9 billion - ETPharma.com
Italian pharma group Chiesi to buy US peer KalVista for $1.9 billion ETPharma.com
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio - Business Wire
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio Business Wire
8-K Filing: KalVista Pharmaceuticals, Inc. (KALV) (CIK 0001348911) — 8-K
8-K
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Impact of Oral Sebetralstat on Anxiety Associated With Hereditary Angioedema Attacks.
Impact of injectable HAE on-demand treatments on health-related quality of life: a patient and caregiver interview study.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo